Document is current
Any future updates will be listed below
-
Authors
Schwarzlmueller, Paul https://orcid.org/0000-0003-0772-5242
Triebig, Alexandra https://orcid.org/0009-0002-4728-0014
Assié, Guillaume
Jouinot, Anne https://orcid.org/0000-0002-7922-2065
Theurich, Sebastian
Maier, Tanja
Beuschlein, Felix
Kobold, Sebastian https://orcid.org/0000-0002-5612-4673
Kroiss, Matthias https://orcid.org/0000-0002-7628-3161
- License Information
-
More Information
Article History
Accepted: 27 February 2025
First Online: 24 March 2025
Competing interests
: M.K. has received institutional remuneration (to institution) for contract research from Corcept, Inc. S.K. has received honoraria from Cymab, Plectonic, TCR2 Inc., Novartis, BMS, Miltenyi and GSK. S.K. is an inventor of several patents in the field of immuno-oncology. S.K. received license fees from TCR2 Inc. and Carina Biotech. S.K. received research support from Tabby Therapeutics, TCR2 Inc., Plectonic GmBH, Catalym GmBH and Arcus Bioscience for work unrelated to the manuscript.
